Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) trials often require a recent biopsy or a specific fibrosis stage on imaging. Alcohol use, other liver diseases, and diabetes control are common filters. We keep the registry wording for those rules. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.
RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE) for Nonalcoholic Fatty Liver Disease (NAFLD)Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).
NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)
RecruitingPhase 1San Francisco, California
Phase 1: testing Bicalutamide 50 mg for NAFLDNonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years. Women are at disproportionate risk for NASH, with approximately 15 million U.S.
NCT05979389 · Official ClinicalTrials.gov record · University of California, San Francisco
RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Efruxifermin for NASH With FibrosisThis is a multi-center evaluation of efruxifermin (EFX) in a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
NCT06215716 · Official ClinicalTrials.gov record · Akero Therapeutics, Inc
RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Pegozafermin for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With FibrosisThe study will assess the how well it works and safety of 2 dose regimens of pegozafermin compared to dummy treatment (placebo) for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.
NCT06318169 · Official ClinicalTrials.gov record · Hoffmann-La Roche
RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Pegozafermin for Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated CirrhosisThe study will assess the how well it works and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .
NCT06419374 · Official ClinicalTrials.gov record · Hoffmann-La Roche
RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Efruxifermin for NASH - Nonalcoholic SteatohepatitisThis is a multi-center evaluation of efruxifermin (EFX) in a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study in subjects with compensated cirrhosis due to NASH/MASH.
NCT06528314 · Official ClinicalTrials.gov record · Akero Therapeutics, Inc
RecruitingNot a traditional drug phaseMiami, Florida
Evaluation of Non-Invasive Tests for Metabolic Liver DiseaseThe Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.
NCT07122700 · Official ClinicalTrials.gov record · Foundation for the National Institutes of Health
RecruitingPhase 3Tuscaloosa, Alabama
Phase 3: testing Tirzepatide for Metabolic Dysfunction-Associated Steatotic Liver DiseaseThe main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO.
NCT07165028 · Official ClinicalTrials.gov record · Eli Lilly and Company
RecruitingPhase 2Chandler, Arizona
Phase 2: testing Placebo for Metabolic Dysfunction-associated SteatohepatitisThe primary objective of this trial is to measure the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.
NCT07288138 · Official ClinicalTrials.gov record · Eccogene
RecruitingPhase 2Tucson, Arizona
Phase 2: testing ALN-PNP for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty liver disease. ALN-PNP reduces the amount of Patatin-like phospholipase domain-containing protein 3 (PNPLA3), a protein that liver cells make, which may help decrease liver fat if there is an abnormal PNPLA3 protein.
NCT07527910 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals